Lumibird Medical recently unveiled the OMNICAD, an imaging platform featuring integrated artificial intelligence (AI) algorithms for ocular surface disease (OSD) diagnosis.
First up: Lumibird.
Lumibird Medical was formed as a result of a 2020 merger between Quantel Medical, Optotek, and Ellex Medical Lasers.
In December 2022, the company launched its flagship product: the Tango Reflex Neo laser.
- In April 2023, Lumibird released newer versions of the Tango Reflex lasers, complete with features giving eyecare professionals (ECP) more precise control and visualization during laser treatments.
Now this new product.
Manufactured by Quantel Medical, a subsidiary of Lumibird, the imaging platform is marketed as “the most complete automatic premium imaging platform dedicated to [OSDs].”
Along with AI-integrated algorithms, OMNICAD is based on “millions” of clinically-validated images such as:
- Blinks
- Tear stability
- Lipid layer
- Tear meniscus
- Standard transillumination meibography
Let’s talk features.
Per the product website, it’s equipped with three key “advantages” that set it apart from other platforms:
- Exclusive meibography
- OMNICAD’s eyelid everter enables the ability to quantify and qualify meibomian gland dysfunction (MGD) by integrating with transillumination infrared light to obtain two meibography images with one click:
- In standard infrared (to quantify glands)
- In transillumination infrared (to determine glands’ functionality)
- Includes capturing glands’ obstruction, accumulation of meibum, and the telangiectasias surrounding them
- OMNICAD’s eyelid everter enables the ability to quantify and qualify meibomian gland dysfunction (MGD) by integrating with transillumination infrared light to obtain two meibography images with one click:
- High imaging quality
- Featuring high precision in analysis, the system includes:
- High-definition (HD) touch screen (2x more pixels than a standard screen)
- Unique optical module plus an HD autofocus camera with a novel liquid lens
- Featuring high precision in analysis, the system includes:
- AI algorithms
- Software-embedded AI and algorithms automatically detect, quantify, and classify diseases; results are then computed into a report (more on that later)
- Note: These deep learning algorithms are “based on more than a million of precise images”
- A graphics processing unit (GPU) card and computer are designed to provide high capacity of data management, data storage, and fast result analysis
- Software-embedded AI and algorithms automatically detect, quantify, and classify diseases; results are then computed into a report (more on that later)
How is the system’s interface set up?
Intended to be “intuitive, friendly, and easy to use,” the OMNICAD features a large screen visualization and full connectivity with DICOM, USB & HDMI ports, WiFi, Bluetooth, Ethernet, and Remote mode.
Also enabled are customizable exam protocols and an automatic analysis, generating a results report via one click.
- Included in this: an easy-to-interpret exams report and suggested diagnosis
And what other testing is offered?
Quite a few—including in colors, fluorescein, and triage and symptoms questionnaires:
- Dry Eye Questionnaire (DEQ)-5
- Ocular Surface Disease Index (OSDI)
- Standard Patient Evaluation of Eye Dryness (SPEED)
As well as grading scales:
- Efron
- Oxford
- Guillon
So how is the system configured?
Three configurations are available, depending on the type of exam performed:
- Standard configuration
- Configuration with secondary screen for exam visualization by a patient
- Configuration with a dedicated exam table and keyboard drawer
This sounds pretty versatile … so where can I find it?
Lumibird noted that the imaging platform is now exclusively available in the U.S. market.
For clinicians interested in their purchasing options, click here to learn more.
How about a demo opportunity?
If you’re attending the American Academy of Ophthalmology (AAO) annual meeting next month, check out the Lumibird booth (#5221) to see the OMNICAD platform.
Academy 2024 kicks off Oct. 18-21 in Chicago, Illinois.